Search results
Jump to navigation
Jump to search
Page title matches
- ==Anatomy of a platelet== ...brand factor]]), the contents of which are released upon activation of the platelet. These granule contents play an important role in both [[hemostasis]] and i12 KB (1,658 words) - 08:52, 28 June 2011
- 12 bytes (1 word) - 09:26, 13 November 2007
- 76 bytes (9 words) - 17:41, 22 June 2008
- ..."series of progressive, overlapping events, triggered by exposure of the [[platelet]]s to subendothelial tissue. These events include shape change, adhesivenes Platelet activation, along with [[coagulation]], leads to [[hemostasis]].573 bytes (73 words) - 03:16, 7 October 2013
- #Redirect [[Platelet activation]]33 bytes (3 words) - 23:51, 29 April 2008
- Auto-populated based on [[Special:WhatLinksHere/Platelet]]. Needs checking by a human. {{r|Platelet activation}}955 bytes (116 words) - 19:35, 11 January 2010
- 166 bytes (20 words) - 09:34, 8 September 2009
- ...antagonize or impair any mechanism leading to blood [[platelet activation|platelet aggregation]], whether during the phases of activation and shape change or Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]4 KB (543 words) - 01:43, 8 May 2013
- #redirect [[Platelet aggregation inhibitors]]45 bytes (4 words) - 09:48, 29 April 2008
- #REDIRECT [[Platelet aggregation inhibitors]]45 bytes (4 words) - 08:13, 23 November 2010
- #Redirect [[Platelet aggregation inhibitors]]45 bytes (4 words) - 23:50, 29 April 2008
- Agents that antagonize or impair any mechanism leading to blood platelet aggregation.122 bytes (15 words) - 09:35, 8 September 2009
- {{r|Platelet aggregation inhibitors|Platelet aggregation inhibitor}}215 bytes (22 words) - 17:24, 27 August 2008
- .../cgi/mesh/2008/MB_cgi?term=Platelet+Glycoprotein+GPIIb-IIIa+Complex |title=Platelet Glycoprotein GPIIb-IIIa Complex |accessdate=2008-01-10 |author=Anonymous |a ...irofiban]], block the platelet glycoprotein GPIIb-IIIa complex and inhibit platelet aggregation. They arp used to treat [[vascular disease]]s.2 KB (291 words) - 21:55, 14 February 2010
- #REDIRECT [[Platelet glycoprotein GPIIb-IIIa complex]]54 bytes (5 words) - 08:28, 11 January 2008
- {{r|Platelet activation}}151 bytes (16 words) - 17:22, 27 August 2008
- 12 bytes (1 word) - 21:41, 22 January 2008
- Integrin receptor found on platelets for fibrinogen, and aids in platelet activation.122 bytes (15 words) - 09:37, 8 September 2009
- Auto-populated based on [[Special:WhatLinksHere/Platelet glycoprotein GPIIb-IIIa complex]]. Needs checking by a human. {{r|Platelet aggregation inhibitors}}562 bytes (68 words) - 19:35, 11 January 2010
Page text matches
- *[[Platelet activation]] **[[Platelet aggregation inhibitor]]157 bytes (11 words) - 04:36, 10 June 2008
- ..."series of progressive, overlapping events, triggered by exposure of the [[platelet]]s to subendothelial tissue. These events include shape change, adhesivenes Platelet activation, along with [[coagulation]], leads to [[hemostasis]].573 bytes (73 words) - 03:16, 7 October 2013
- {{r|Platelet activation}} {{r|Platelet aggregation inhibitor}}142 bytes (16 words) - 23:05, 17 February 2009
- {{r|Platelet activation}} {{r|Platelet aggregation inhibitors|Platelet aggregation inhibitor|**}}263 bytes (27 words) - 00:30, 3 March 2010
- #redirect [[Platelet]]22 bytes (2 words) - 15:23, 15 February 2007
- ...are deficient in or have a defect in the glycoprotein IIb-IIIa complex ([[Platelet glycoprotein GPIIb-IIIa complex]])."<ref name="MeSH-Thrombasthenia">{{MeSH}441 bytes (55 words) - 00:49, 14 September 2013
- #Redirect [[Platelet activation]]33 bytes (3 words) - 23:51, 29 April 2008
- #redirect [[Platelet aggregation inhibitors]]45 bytes (4 words) - 09:48, 29 April 2008
- #REDIRECT [[Platelet aggregation inhibitors]]45 bytes (4 words) - 19:26, 16 October 2011
- #REDIRECT [[Platelet aggregation inhibitors]]45 bytes (4 words) - 15:21, 23 January 2014
- #REDIRECT [[Platelet aggregation inhibitors]]45 bytes (4 words) - 08:13, 23 November 2010
- #REDIRECT [[Platelet aggregation inhibitors]]45 bytes (4 words) - 09:00, 23 November 2010
- #Redirect [[Platelet aggregation inhibitors]]45 bytes (4 words) - 23:50, 29 April 2008
- #REDIRECT [[Platelet glycoprotein GPIIb-IIIa complex]]54 bytes (5 words) - 08:28, 11 January 2008
- {{r|Platelet aggregation inhibitors|Platelet aggregation inhibitor}}215 bytes (22 words) - 17:24, 27 August 2008
- .../cgi/mesh/2008/MB_cgi?term=Platelet+Glycoprotein+GPIIb-IIIa+Complex |title=Platelet Glycoprotein GPIIb-IIIa Complex |accessdate=2008-01-10 |author=Anonymous |a ...irofiban]], block the platelet glycoprotein GPIIb-IIIa complex and inhibit platelet aggregation. They arp used to treat [[vascular disease]]s.2 KB (291 words) - 21:55, 14 February 2010
- {{r|Platelet activation}} {{r|Platelet aggregation inhibitors}}992 bytes (122 words) - 11:06, 11 January 2010
- A platelet aggregation inhibitor used to prevent cardiac events99 bytes (12 words) - 00:32, 16 March 2009
- Agents that antagonize or impair any mechanism leading to blood platelet aggregation.122 bytes (15 words) - 09:35, 8 September 2009
- Hemostasis consists of [[coagulation]] and [[platelet activation]]. For medical purposes, hemostasis can be inhibited by [[anticoagulant]]a or [[platelet aggregation inhibitor]]s.534 bytes (70 words) - 02:47, 7 October 2013
- Integrin receptor found on platelets for fibrinogen, and aids in platelet activation.122 bytes (15 words) - 09:37, 8 September 2009
- Auto-populated based on [[Special:WhatLinksHere/Platelet glycoprotein GPIIb-IIIa complex]]. Needs checking by a human. {{r|Platelet aggregation inhibitors}}562 bytes (68 words) - 19:35, 11 January 2010
- {{r|Platelet aggregation inhibitors}} {{r|Platelet}}638 bytes (80 words) - 11:56, 11 January 2010
- {{r|Platelet glycoprotein GPIIb-IIIa complex}} {{r|Platelet}}682 bytes (83 words) - 21:00, 11 January 2010
- ...)|plasma]]; the primary types being [[erythrocyte]]s, [[leukocyte]]s and [[platelet]]s176 bytes (23 words) - 13:02, 4 June 2010
- Auto-populated based on [[Special:WhatLinksHere/Platelet]]. Needs checking by a human. {{r|Platelet activation}}955 bytes (116 words) - 19:35, 11 January 2010
- ...[[Adenosine diphosphate|ADP]] or [[Adenosine triphosphate|ATP]] mediates [[platelet]] aggregation.232 bytes (26 words) - 10:54, 14 December 2009
- '''Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit''' (or PAFAH1B250 bytes (34 words) - 08:53, 22 January 2009
- ...d components (or whole blood) such as [[erythrocyte]]s, [[leukocyte]]s, [[platelet]]s, and plasma from a donor to a recipient or back to the donor. Blood comp * [[Platelet transfusion]]998 bytes (129 words) - 05:35, 30 January 2011
- ...atelet]]s by fragmenting into small, odd-shaped pieces. These fragments ([[platelet]]s) of the megakaryocyte's [[cytoplasm]] circulate in the blood as the body ...its contents all at once in the marrow. Alternatively, the cell may form platelet ribbons into blood vessels. The ribbons are formed via psuedopodia and the2 KB (296 words) - 10:44, 10 June 2010
- {{r|Platelet}}195 bytes (22 words) - 15:14, 30 June 2009
- {{r|Platelet}}178 bytes (19 words) - 21:09, 10 December 2009
- {{r|Platelet activation}}151 bytes (16 words) - 17:22, 27 August 2008
- In [[pharmacology]], '''prasugrel''' is a [[platelet aggregation inhibitor]] of the [[thienopyridine]] class that blocks [[adeno406 bytes (38 words) - 17:36, 13 July 2011
- {{r|Platelet}}362 bytes (44 words) - 11:50, 15 February 2009
- ...' include [[eptifibatide]] and [[tirofiban]]. These medication block the [[platelet glycoprotein GPIIb-IIIa complex]] and are used for treating [[acute coronar671 bytes (85 words) - 10:09, 17 October 2010
- {{r|Platelet||**}}556 bytes (65 words) - 22:32, 2 June 2010
- ...d concentration, reduces incidence of cardiovascular disorders, prevents [[platelet aggregation]], and inhibits [[arachidonic acid]] conversion into the [[thro540 bytes (63 words) - 03:15, 7 October 2013
- {{r|Platelet glycoprotein GPIIb-IIIa complex}}469 bytes (58 words) - 16:53, 11 January 2010
- {{r|Platelet}}618 bytes (73 words) - 13:59, 26 November 2010
- ...nal |author=Fritz E, Ludwig H, Scheithauer W, Sinzinger H |title=Shortened platelet half-life in multiple myeloma |journal=Blood |volume=68 |issue=2 |pages=514 ...s Disease. The chronic form in adults is usually caused by antibodies to [[Platelet glycoprotein GPIIb-IIIa complex]] or Ib-IX.<ref name="isbn0-7216-0187-1"/>4 KB (579 words) - 13:26, 23 November 2010
- .../> This leaves vasoconstriction, platelet aggregation, and thrombosis from platelet thromboxane A2 mediated by COX-1 intact.<ref name="pmid-16968830"/>2 KB (265 words) - 09:16, 28 December 2010
- {{r|Platelet}}588 bytes (71 words) - 16:58, 11 January 2010
- {{r|Platelet}}619 bytes (80 words) - 21:25, 11 January 2010
- {{r|Platelet}}610 bytes (73 words) - 15:48, 11 January 2010
- {{r|Platelet}}651 bytes (80 words) - 10:59, 11 January 2010
- {{r|Platelet}}679 bytes (85 words) - 15:36, 11 January 2010
- ...actor complex. The von Willebrand factor has receptors for [[collagen]], [[platelet]]s, and [[ristocetin]] activity as well as the immunologically distinct ant629 bytes (86 words) - 17:31, 10 July 2010
- {{r|Platelet}}834 bytes (105 words) - 19:56, 11 January 2010
- {{r|Platelet}}759 bytes (101 words) - 15:55, 11 January 2010
- ...'''cangrelor''' is an [[purinergic P2Y receptor antagonist]]s that is a [[platelet aggregation inhibitor]]. ...Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW et al.| title=Effect of platelet inhibition with cangrelor during PCI on ischemic events. | journal=N Engl J6 KB (873 words) - 12:25, 27 August 2013
- {{r|Platelet}}828 bytes (107 words) - 22:30, 17 April 2011
- {{r|Platelet transfusion}}816 bytes (122 words) - 01:41, 15 November 2010
- ...antagonize or impair any mechanism leading to blood [[platelet activation|platelet aggregation]], whether during the phases of activation and shape change or Inhibitors of the [[platelet glycoprotein GPIIb-IIIa complex]] (GPIs) include the [[monoclonal antibody]4 KB (543 words) - 01:43, 8 May 2013
- {{r|Platelet}}1 KB (147 words) - 07:44, 8 January 2010
- {{r|Platelet}}1 KB (146 words) - 21:45, 23 August 2010
- ==Anatomy of a platelet== ...brand factor]]), the contents of which are released upon activation of the platelet. These granule contents play an important role in both [[hemostasis]] and i12 KB (1,658 words) - 08:52, 28 June 2011
- ...nce of [[fibrin]] strands following the mixing of plasma with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of t1 KB (155 words) - 10:43, 23 August 2010
- ...nism of [[phagocytosis]]. They produce [[leukotriene]] C<sub>4</sub> and [[platelet activation factor]] (PAF). <ref name=Ganong>{{citation ...Ganong, p. 508</ref> Especially infectious parasites produce inhibitors of platelet aggregation.<ref name=Liu>{{citation4 KB (579 words) - 22:42, 9 June 2010
- ...of [[hematoepoesis]]: generation of [[erythrocyte]]s, [[leukocyte]]s and [[platelet]]s from [[hematopoetic stem cell]]s.1 KB (202 words) - 20:28, 25 June 2010
- {{r|Platelet||**}}2 KB (192 words) - 08:17, 11 December 2009
- {{r|Platelet-derived growth factor receptor||**}}2 KB (234 words) - 00:42, 13 January 2009
- ...nthase]] by acetylating its terminal amino group. Aspirin also inhibits [[platelet]] aggregation and is used in the prevention of arterial and venous [[thromb Individuals in whom platelet function assays demonstrate resistance to aspirin are less likely to have c4 KB (523 words) - 14:17, 26 July 2017
- ...s]] include [[leukocyte]]s for immune and infection-fighting action, and [[platelet]]s for clotting.2 KB (261 words) - 09:00, 1 March 2024
- ...eptor]]s, and [[purinoceptor P2Y12|purinoceptor P2Y<sub>12</sub>]] (causes platelet aggregation).3 KB (338 words) - 13:08, 30 March 2010
- *[[Platelet]]s per unit volume2 KB (257 words) - 12:46, 30 January 2011
- ...ansduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway."<ref>{{MeSH}}</ref>2 KB (329 words) - 10:52, 9 July 2009
- ...('''TTP''') is "an acquired, congenital, or familial disorder caused by [[platelet aggregation]] with [[thrombosis]] in terminal arterioles and capillaries. C2 KB (310 words) - 21:03, 25 September 2013
- ...hich leads to profound low [[white blood cell]], [[red blood cell]], and [[platelet]] counts.2 KB (280 words) - 23:21, 10 June 2010
- ...does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]].2 KB (338 words) - 13:15, 22 November 2011
- ...ess bleeding, particularly since the patient has typically been given anti-platelet medications during the procedure. The duration of anti-platelet therapy is uncertain.<ref name="pmid20231231">{{cite journal| author=Park S10 KB (1,452 words) - 14:10, 2 February 2023
- ...chemicals, especially [[histamine]]. They also release [[leukotriene]]s, [[platelet aggregation factor]], [[eosinophil chemotactic factor]]-A, and a [[basophi3 KB (399 words) - 16:44, 14 January 2011
- * Pohl's Index is if the AST/ALT ratio ≥1 and platelet count ≤ 150,000/mm<sup>3</sup> then cirrhosis is very likely.<ref name="p ...307/8/832/F3.expansion.html Bonacini score] is based on the ALT/AST ratio, platelet count, and INR.<ref name="pmid16437635">{{cite journal| author=Colli A, Col11 KB (1,523 words) - 12:08, 12 May 2015
- ...al vasculature, [[brain]] || [[vasoconstriction]], [[gluconeogenesis]], [[platelet]] aggregation, and release of [[factor VIII]] and [[von Willebrand factor]]3 KB (394 words) - 09:27, 18 June 2008
- Elevations in [[platelet]]s and [[lactic dehydrogenase]] also can artificially raise the potassium l4 KB (517 words) - 23:17, 9 November 2010
- | Primary NSTEMI: Nonocclusive grayish-white thrombus<br/>(platelet-rich)<br/> ...2738"/> NSTEMI is usually caused by a grayish-white [[thrombus]] that is [[platelet]]-rich.<ref name="pmid1728732">{{cite journal |author=Mizuno K, Satomura K,22 KB (2,922 words) - 09:45, 21 February 2015
- ...ng and clotting times. Large volumes decrease hematocrit, plasma proteins, platelet counts, and hemoglobin.4 KB (492 words) - 23:15, 21 December 2010
- ...f the three types of blood cells: [[erythrocytes]]s, [[leukocyte]]s and [[platelet]]s. Although not a true [[neoplasia|malignant neoplasm]], MDS is neverthel * [[Thrombocytopenia]] (low platelet count)—increased susceptibility to [[bleeding]]17 KB (2,335 words) - 14:10, 2 February 2023
- ...le=Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with10 KB (1,334 words) - 00:14, 31 January 2014
- |Smooth muscle, basophils, mast cells, [[platelet]]s, [[eosinophil]]s4 KB (608 words) - 06:10, 31 May 2009
- ...educes the risk of [[hemorrhage]], they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also4 KB (582 words) - 20:51, 2 March 2010
- ...messenger that triggers a step toward the creation of [[leukocyte]]s or [[platelet]]s from the original [[pluripotent stem cell]]s. GM-CSF actually operates4 KB (601 words) - 23:03, 10 June 2010
- ...age:Red White Blood cells.jpg|thumb|From left to right: [[erythrocyte]], [[Platelet|thrombocyte]], [[leukocyte]].]] ...4,000–11,000 [[white blood cells]] and about 150,000–400,000 [[platelet]]s in a cubic millimeter of human blood. The red blood cells store collecti10 KB (1,571 words) - 04:02, 19 September 2013
- * [[Platelet count]]6 KB (818 words) - 12:51, 8 September 2020
- *Moreover, exposure to cigarette smoke results in [[platelets|platelet]] activation, stimulation of the coagulation cascade, and impairment of ant5 KB (678 words) - 08:07, 30 September 2016
- ...maximum dose of Zevalin is 32 mCi. For previously untreated NHL, however, platelet counts must be a minimum of 150,000/m<sup>3</sup> and treatment must begin11 KB (1,563 words) - 03:38, 7 October 2013
- ...o [[blood component transfusion]] such as [[erythrocyte transfusion]] or [[platelet transfusion]].6 KB (775 words) - 21:57, 14 February 2010
- Coagulation, along with [[platelet activation]], leads to [[hemostasis]]. ...n due to a variety of factors such as coagulation protein disorders; blood platelet disorders; blood protein disorders or nutritional conditions."<ref name="Me13 KB (1,708 words) - 08:01, 12 December 2010
- ...358">{{cite journal| author=Beyan C, Kaptan K, Beyan E, Turan M| title=The platelet count/mean corpuscular hemoglobin ratio distinguishes combined iron and vit6 KB (890 words) - 16:47, 13 May 2023
- ...lume= 20 | issue= 6 | pages= 603-10 | pmid=11075846 }} </ref>|| "The lower platelet 5-HT during treatment with [[citalopram]] than amitriptyline indicates that6 KB (838 words) - 21:18, 4 June 2012
- | Nonocclusive grayish-white thrombus<br/>(platelet-rich) | Primary NSTEMI: Nonocclusive grayish-white thrombus<br/>(platelet-rich)<br/>31 KB (4,213 words) - 07:18, 28 March 2023
- ...asting 2–7 days; 2) positive tourniquet test or spontaneous bleeding; 3) [[platelet]] count 100x10<sup>9</sup>/L or less; 4) plasma leakage shown either by hem6 KB (761 words) - 01:00, 10 January 2008
- ...of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammat14 KB (1,835 words) - 06:45, 27 May 2011
- * Platelet dysfunction6 KB (818 words) - 16:34, 21 December 2010
- * [[Platelet aggregation inhibitors]] and other anti-hemostatic agents according to [[me7 KB (985 words) - 16:38, 9 September 2020
- In [[medicine]], '''clopidogrel''' is a [[thienopyridine]] class [[platelet aggregation inhibitor]]. It is used in the [[secondary prevention]] of [[st7 KB (1,047 words) - 19:45, 16 October 2011
- ...ase in 1996, however, the victim experienced severe hemolysis and complete platelet destruction after which the liver and kidneys began to fail. When it was fe7 KB (949 words) - 14:21, 8 March 2024
- ...*2 [[allele]] may reduce the occurrence of patients with high on-treatment platelet reactivity.<ref name="pmid22464343">{{cite journal| author=Roberts JD, Well8 KB (1,130 words) - 17:34, 10 February 2024
- ===Anti-platelet drugs=== The most effective anti-platelet treatment is probably to combine aspirin, 25 mg twice a day with extended-r17 KB (2,378 words) - 20:33, 9 October 2012
- ...sion properties. Studies have shown that addition of PAF or inhibition of platelet-activating factor acetylhydrolase (PAF-AH) decreases cerebellar granule cel22 KB (3,035 words) - 09:44, 20 February 2024